Why in News?

A new anti-cancer drug named Daraxonrasib has shown encouraging results in treating pancreatic cancer during a Phase 3 clinical trial.

The drug significantly reduced tumour size and halted cancer progression in a majority of patients, offering hope against one of the deadliest forms of cancer.

Detailed Insights:

1. Daraxonrasib targets the KRAS gene mutation found in nearly 95% of pancreatic cancer cases.
   In the clinical trial:
   - Tumour size reduced in 51% of patients.
   - Cancer growth stopped in 97% of patients.
   - Developed by Revolution Medicines.
2. The U.S. Food and Drug Administration (FDA) granted:
   - “National Priority Voucher” status
   - Expanded access approval for patients with no alternative treatment options.

What is Pancreatic Cancer?

Pancreatic cancer occurs when abnormal cells in the pancreas grow uncontrollably.

Why is it Dangerous?

• Usually detected at late stages.
• Symptoms appear very late.
• Limited surgical treatment options.
• Standard chemotherapy often shows poor effectiveness.

It is considered one of the most lethal cancers globally.

Scientific/Technical Concepts Involved: